A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark

Vaccine

Volumn 30, Issue 19, 2012, Pages 3042-3046

  Andrews, Nick ^a   Stowe, Julia ^a   Miller, Elizabeth ^a   Svanström, Henrik ^b   Johansen, Kari ^c   Bonhoeffer, Jan ^d   Hviid, Anders ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b STATENS SERUM INSTITUT   (Denmark)

^c Scientific Advice Unit   (Sweden)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Data linkage; European collaboration; Meta analysis; MMR vaccine; Thrombocytopenic purpura; Vaccine safety; VAESCO

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; CHILD; DENMARK; DRUG SAFETY; HOSPITAL ADMISSION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEASLES; MUMPS; PRESCHOOL CHILD; PRIORITY JOURNAL; RUBELLA; THROMBOCYTOPENIC PURPURA; UNITED KINGDOM; VACCINATION;

ADOLESCENT; ADULT; COHORT STUDIES; DENMARK; DRUG TOXICITY; ENGLAND; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INTERNATIONAL COOPERATION; MALE; MEASLES-MUMPS-RUBELLA VACCINE; PURPURA, THROMBOCYTOPENIC; RISK ASSESSMENT; VACCINATION; YOUNG ADULT;

EID: 84859435556     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.009     Document Type: Article

References (19)

1. Madsen K.M., Hviid A., Vestergaard M., Schendel D., Wohlfahrt J., Thorsen P., et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002, 347(November (19)):1477-1482.
2. Miller E., Andrews N., Grant A., Stowe J., Taylor B. No evidence of an association between measles, mumps and rubella vaccination and gait disturbance. Arch Dis Child 2005, 90:292-296.
3. Vestergaard M., Hviid A., Madsen K.M., Wohlfahrt J., Thorsen P., Schendel D., et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004, 292(July (3)):351-357.
4. Mantadakis E., Farmaki E., Buchanan G.R. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr 2010, 156(April (4)):623-628.
5. Klein N.P., Fireman B., Yih W.K., Lewis E., Kulldorff M., Ray P., et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010, 126(July (1)):e1-8.
6. Black S. Global Vaccine Safety DataNet meeting. Expert Rev Vaccines 2008, 7(February (1)):15-20.
7. Eurosurveillance Editorial Team ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe. Eur Surveill 2009, 14(October (39)).
8. Chen R.T., Glasser J.W., Rhodes P.H., Davis R.L., Barlow W.E., Thompson R.S., et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997, 99(June (6)):765-773.
9. Farrington P., Pugh S., Colville A., Flower A., Nash J., Morgan-Capner P., et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps rubella vaccine. Lancet 1995, 345:567-569.
10. Hviid A. Postlicensure epidemiology of childhood vaccination: the Danish experience. Expert Rev Vaccines 2006, 5(October (5)):641-649.
11. Wise R.P., Bonhoeffer J., Beeler J., Donato H., Downie P., Matthews D., et al. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(31):5717-5724.
12. Zeller B., Rajantie J., Hedlund-Treutiger I., Tedgard U., Wesenberg F., Jonsson O.G., et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr 2005, 94(2):178-184.
13. Glanz J., France E., Xu S., Hayes T., Hambidge S. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pediatrics 2008, 121(March (3)):e506-e512.
14. Bachand A.J., Rubenstein J., Morrison A.N. Thrombocytopenic purpura following live measles vaccine. Am J Dis Child 1967, 113(February (2)):283-285.
15. Stratton K.R., Howe C.J., Johnston R.B. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994, 271(May (20)):1602-1605.
16. Miller E., Waight P., Farrington C.P., Andrews N., Stowe J., Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001, 84(3):227-229.
17. France E.K., Glanz J., Xu S., Hambidge S., Yamasaki K., Black S.B., et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics 2008, 121(March (3)):e687-e692.
18. Malig C. The Civil Registration System in Denmark. IIVRS Technical Paper, No. 66. Bethesda, Maryland: International Institute for Vital Registration and Statistics; 1996.
19. Whitaker H.J., Hocine M.N., Farrington C.P. The methodology of self-controlled case series studies. Stat Methods Med Res 2009, 18(February (1)):7-26.